דלגו לתוכן

Belite Bio החלה בסיקור עם המלצת קנייה (Overweight) במורגן סטנלי

דה פליי (TheFly)6 בינואר 2026
Belite Bio החלה בסיקור עם המלצת קנייה (Overweight) במורגן סטנלי

Morgan Stanley initiated coverage of Belite Bio (BLTE) with an Overweight rating and $191 price target The firm says its key opinion leader checks support a multi-billion dollar opportunity for tinlarebant in Stargardt disease type 1. Potential regulatory approval and commercial launch are catalysts to move shares higher over the next 12 months, the analyst tells investors in a research note.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>